Pacira stock downgraded amid eVenus approval concerns - Barclays By Investing.com - Investing.com
Pacira BioSciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $23.22
+4.7% in 3d after detection
Post-detection moves
1h
—
1d
+3.1%
3d
+4.7%
7d
+4.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS